PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “ETHICS, PHARMACEUTICAL”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 775 records · Page 43Linked to original sources
PubMed1983

Drug therapy in childhood: what has been done and what has to be done?

Exactly 30 years ago the German pediatrician Dost introduced the concept of pharmacokinetics into clinical and experimental research. In the following years this concept prompted a rapidly increasing understanding of the mechanisms of drug disposition and of host factors as major determinants of drug concentration and, in consequence, of drug effect within the organism. This has led to a burgeoning new discipline--clinical pharmacology. However, the pharmacokinetic approach was, with few exceptions, not particularly cherished by the pediatricians, until dramatic clinical accidents, such as the chloramphenicol-gray syndrome and the thalidomide-phocomelia tragedies occurred, which highlighted the pharmacokinetic, and pharmacodynamic, features of the growing organism, especially of the fetus, newborn, and young infant. In the 1970s, the explosive development of sensitive and specific methods for the analysis of nearly all drugs in body fluids and tissues and the great progress in computer technology induced an enormous progress in clinical pharmacokinetics making age-related drug and dosage recommendations possible, which were based on scientific data, and initiating therapeutic drug monitoring. However, years ago, in 1965, von Harnack and others published pediatric drug dosage recommendations based on empiric data realizing that, for many drugs, an appropriate dosage schedule can be achieved when the drug dose is calculated according to body surface area rather than to body weight. While advances in pediatric pharmacokinetics have been proceeding at a rapid pace during the last decade, it is quite evident that the progress in pharmacodynamics has lagged far behind the research and attention paid to pharmacokinetics. For the future increasing work concerning the quantitation of clinical effects in correlation to drug dosage and drug level is urgently needed. That holds true for short-term and for long-term clinical effects of drugs given to newborns, infants, and children, as well as for adverse and for desired therapeutic effects of drugs administered to an unborn via his mother. Undoubtedly, quantitative determination of clinical drug effects is much more difficult than quantitation of pharmacokinetics, not only for technical, but also for ethical reasons. Moreover, pharmacodynamic studies in long-term treatment of chronically ill children are complicated by the problem of the patient's compliance. However, the rapid progress in pediatric oncology in the past is an impressive example for the usefulness of controlled clinical trials based on pharmacodynamic rather than pharmacokinetic criteria.

Age Factors↗
PubMed1994

The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.

Physicians increasingly use Food and Drug Administration (FDA)-approved drugs (medication) for unlabeled (off-label) indications. The ethical and legal implications of these actions are not always clear. In this article, I examine the common law and federal statutory regulations concerning this issue and also explore some of the ethical and financial issues involved.

Beneficence↗
PubMedDate not supplied

Secondary pharmaceuticals manufacturing.

Drs. Burling and Shah examine the second part of the pharmaceuticals manufacturing process, in which formulations for drug delivery are determined. Several types of formulations and their potentials for occupational exposure are reviewed.

Administration, Topical↗
PubMed1976

[Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].

Drugs should be effective for the indicatons stated, they should not involve risks which would not be justified in relation to their benefit and they should be of the necessary quality. It is the objective of drug legislation to warrant these requirements in its area of jurisdiction. It has become a necessity to revise current legislation; it is going to be replaced by a new law. A corresponding bill is being considered by Parliament at present. The present and the future legal situation with regards to proof and safeguarding of the bioavailability of pharmacologically active substances and the necessary prerequisites and rules for the procedure of clinical testing of drugs to prove their efficacy and safety is described.

Animals↗